- The Japanese Ministry of Health, Labor and Welfare approves GlaxoSmithKline (GSK) and Theravance's (THRX) Anoro Ellipta (umeclidinium/vilanterol) for the relief of various symptoms of chronic obstructive pulmonary diseases in patients who require the concurrent use of a long-acting inhaled muscarinic antagonist and a long-acting inhaled beta2 agonist.
- Anoro is a once-daily treatment comprised of two broncodilators. Umeclidinium is the muscarinic antagonist and vilanterol is the beta2 agonist.
- Under the terms of the companies' 2002 collaboration agreement, Theravance is obligated to pay Glaxo a milestone payment of $10M based on Japanese regulatory approval.
From other sites
at CNBC.com (May 28, 2015)
Video at CNBC.com (May 11, 2015)
Video at CNBC.com (May 6, 2015)
Video at CNBC.com (Jan 23, 2015)
at CNBC.com (Jan 6, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs